Susceptibility of highly pathogenic A(H5N1) avian influenza viruses to the neuraminidase inhibitors and adamantanes.
Identifieur interne : 003A70 ( Main/Exploration ); précédent : 003A69; suivant : 003A71Susceptibility of highly pathogenic A(H5N1) avian influenza viruses to the neuraminidase inhibitors and adamantanes.
Auteurs : A C Hurt [Australie] ; P. Selleck ; N. Komadina ; R. Shaw ; L. Brown ; I G BarrSource :
- Antiviral research [ 0166-3542 ] ; 2007.
Descripteurs français
- KwdFr :
- Amantadine (analogues et dérivés), Amantadine (pharmacologie), Animaux (MeSH), Antienzymes (pharmacologie), Antiviraux (pharmacologie), Cyclopentanes (pharmacologie), Grippe chez les oiseaux (virologie), Grippe humaine (virologie), Guanidines (pharmacologie), Humains (MeSH), Oiseaux (MeSH), Oséltamivir (pharmacologie), Résistance virale aux médicaments (MeSH), Sialidase (antagonistes et inhibiteurs), Sialidase (génétique), Sous-type H5N1 du virus de la grippe A (effets des médicaments et des substances chimiques), Sous-type H5N1 du virus de la grippe A (génétique), Sous-type H5N1 du virus de la grippe A (isolement et purification), Séquence nucléotidique (MeSH), Zanamivir (pharmacologie).
- MESH :
- analogues et dérivés : Amantadine.
- antagonistes et inhibiteurs : Sialidase.
- effets des médicaments et des substances chimiques : Sous-type H5N1 du virus de la grippe A.
- génétique : Sialidase, Sous-type H5N1 du virus de la grippe A.
- isolement et purification : Sous-type H5N1 du virus de la grippe A.
- pharmacologie : Amantadine, Antienzymes, Antiviraux, Cyclopentanes, Guanidines, Oséltamivir, Zanamivir.
- virologie : Grippe chez les oiseaux, Grippe humaine.
- Animaux, Humains, Oiseaux, Résistance virale aux médicaments, Séquence nucléotidique.
English descriptors
- KwdEn :
- Amantadine (analogs & derivatives), Amantadine (pharmacology), Animals (MeSH), Antiviral Agents (pharmacology), Base Sequence (MeSH), Birds (MeSH), Cyclopentanes (pharmacology), Drug Resistance, Viral (MeSH), Enzyme Inhibitors (pharmacology), Guanidines (pharmacology), Humans (MeSH), Influenza A Virus, H5N1 Subtype (drug effects), Influenza A Virus, H5N1 Subtype (genetics), Influenza A Virus, H5N1 Subtype (isolation & purification), Influenza in Birds (virology), Influenza, Human (virology), Neuraminidase (antagonists & inhibitors), Neuraminidase (genetics), Oseltamivir (pharmacology), Zanamivir (pharmacology).
- MESH :
- chemical , analogs & derivatives : Amantadine.
- chemical , antagonists & inhibitors : Neuraminidase.
- chemical , genetics : Neuraminidase.
- chemical , pharmacology : Amantadine, Antiviral Agents, Cyclopentanes, Enzyme Inhibitors, Guanidines, Oseltamivir, Zanamivir.
- drug effects : Influenza A Virus, H5N1 Subtype.
- genetics : Influenza A Virus, H5N1 Subtype.
- isolation & purification : Influenza A Virus, H5N1 Subtype.
- virology : Influenza in Birds, Influenza, Human.
- Animals, Base Sequence, Birds, Drug Resistance, Viral, Humans.
Abstract
Since 2003, highly pathogenic A(H5N1) influenza viruses have been the cause of large-scale death in poultry and the subsequent infection and death of over 140 humans. A group of 55 influenza A(H5N1) viruses isolated from various regions of South East Asia between 2004 and 2006 were tested for their susceptibility to the anti-influenza drugs the neuraminidase inhibitors and adamantanes. The majority of strains were found to be fully sensitive to the neuraminidase inhibitors oseltamivir carboxylate, zanamivir and peramivir; however two strains demonstrated increased IC50 values. Sequence analysis of these strains revealed mutations in the normally highly conserved residues 116 and 117 of the N1 neuraminidase. Sequence analysis of the M2 gene showed that all of the A(H5N1) viruses from Vietnam, Malaysia and Cambodia contained mutations (L26I and S31N) associated with resistance to the adamantane drugs (rimantadine and amantadine), while strains from Indonesia were found to be a mix of both adamantane resistant (S31N) and sensitive viruses. None of the A(H5N1) viruses from Myanmar contained mutations known to confer adamantane resistance. These results support the use of neuraminidase inhibitors as the most appropriate class of antiviral drug to prevent or treat human A(H5N1) virus infections.
DOI: 10.1016/j.antiviral.2006.10.004
PubMed: 17112602
Affiliations:
Links toward previous steps (curation, corpus...)
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Susceptibility of highly pathogenic A(H5N1) avian influenza viruses to the neuraminidase inhibitors and adamantanes.</title><author><name sortKey="Hurt, A C" sort="Hurt, A C" uniqKey="Hurt A" first="A C" last="Hurt">A C Hurt</name><affiliation wicri:level="1"><nlm:affiliation>World Health Organisation Collaborating Centre for Reference and Research on Influenza, 45 Poplar Road, Parkville, Victoria 3052, Australia. Aeron.Hurt@influenzacentre.org</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>World Health Organisation Collaborating Centre for Reference and Research on Influenza, 45 Poplar Road, Parkville, Victoria 3052</wicri:regionArea><wicri:noRegion>Victoria 3052</wicri:noRegion></affiliation></author><author><name sortKey="Selleck, P" sort="Selleck, P" uniqKey="Selleck P" first="P" last="Selleck">P. Selleck</name></author><author><name sortKey="Komadina, N" sort="Komadina, N" uniqKey="Komadina N" first="N" last="Komadina">N. Komadina</name></author><author><name sortKey="Shaw, R" sort="Shaw, R" uniqKey="Shaw R" first="R" last="Shaw">R. Shaw</name></author><author><name sortKey="Brown, L" sort="Brown, L" uniqKey="Brown L" first="L" last="Brown">L. Brown</name></author><author><name sortKey="Barr, I G" sort="Barr, I G" uniqKey="Barr I" first="I G" last="Barr">I G Barr</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2007">2007</date><idno type="RBID">pubmed:17112602</idno><idno type="pmid">17112602</idno><idno type="doi">10.1016/j.antiviral.2006.10.004</idno><idno type="wicri:Area/Main/Corpus">003C79</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">003C79</idno><idno type="wicri:Area/Main/Curation">003C79</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Curation">003C79</idno><idno type="wicri:Area/Main/Exploration">003C79</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Susceptibility of highly pathogenic A(H5N1) avian influenza viruses to the neuraminidase inhibitors and adamantanes.</title><author><name sortKey="Hurt, A C" sort="Hurt, A C" uniqKey="Hurt A" first="A C" last="Hurt">A C Hurt</name><affiliation wicri:level="1"><nlm:affiliation>World Health Organisation Collaborating Centre for Reference and Research on Influenza, 45 Poplar Road, Parkville, Victoria 3052, Australia. Aeron.Hurt@influenzacentre.org</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>World Health Organisation Collaborating Centre for Reference and Research on Influenza, 45 Poplar Road, Parkville, Victoria 3052</wicri:regionArea><wicri:noRegion>Victoria 3052</wicri:noRegion></affiliation></author><author><name sortKey="Selleck, P" sort="Selleck, P" uniqKey="Selleck P" first="P" last="Selleck">P. Selleck</name></author><author><name sortKey="Komadina, N" sort="Komadina, N" uniqKey="Komadina N" first="N" last="Komadina">N. Komadina</name></author><author><name sortKey="Shaw, R" sort="Shaw, R" uniqKey="Shaw R" first="R" last="Shaw">R. Shaw</name></author><author><name sortKey="Brown, L" sort="Brown, L" uniqKey="Brown L" first="L" last="Brown">L. Brown</name></author><author><name sortKey="Barr, I G" sort="Barr, I G" uniqKey="Barr I" first="I G" last="Barr">I G Barr</name></author></analytic><series><title level="j">Antiviral research</title><idno type="ISSN">0166-3542</idno><imprint><date when="2007" type="published">2007</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Amantadine (analogs & derivatives)</term><term>Amantadine (pharmacology)</term><term>Animals (MeSH)</term><term>Antiviral Agents (pharmacology)</term><term>Base Sequence (MeSH)</term><term>Birds (MeSH)</term><term>Cyclopentanes (pharmacology)</term><term>Drug Resistance, Viral (MeSH)</term><term>Enzyme Inhibitors (pharmacology)</term><term>Guanidines (pharmacology)</term><term>Humans (MeSH)</term><term>Influenza A Virus, H5N1 Subtype (drug effects)</term><term>Influenza A Virus, H5N1 Subtype (genetics)</term><term>Influenza A Virus, H5N1 Subtype (isolation & purification)</term><term>Influenza in Birds (virology)</term><term>Influenza, Human (virology)</term><term>Neuraminidase (antagonists & inhibitors)</term><term>Neuraminidase (genetics)</term><term>Oseltamivir (pharmacology)</term><term>Zanamivir (pharmacology)</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Amantadine (analogues et dérivés)</term><term>Amantadine (pharmacologie)</term><term>Animaux (MeSH)</term><term>Antienzymes (pharmacologie)</term><term>Antiviraux (pharmacologie)</term><term>Cyclopentanes (pharmacologie)</term><term>Grippe chez les oiseaux (virologie)</term><term>Grippe humaine (virologie)</term><term>Guanidines (pharmacologie)</term><term>Humains (MeSH)</term><term>Oiseaux (MeSH)</term><term>Oséltamivir (pharmacologie)</term><term>Résistance virale aux médicaments (MeSH)</term><term>Sialidase (antagonistes et inhibiteurs)</term><term>Sialidase (génétique)</term><term>Sous-type H5N1 du virus de la grippe A (effets des médicaments et des substances chimiques)</term><term>Sous-type H5N1 du virus de la grippe A (génétique)</term><term>Sous-type H5N1 du virus de la grippe A (isolement et purification)</term><term>Séquence nucléotidique (MeSH)</term><term>Zanamivir (pharmacologie)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="analogs & derivatives" xml:lang="en"><term>Amantadine</term></keywords><keywords scheme="MESH" type="chemical" qualifier="antagonists & inhibitors" xml:lang="en"><term>Neuraminidase</term></keywords><keywords scheme="MESH" type="chemical" qualifier="genetics" xml:lang="en"><term>Neuraminidase</term></keywords><keywords scheme="MESH" type="chemical" qualifier="pharmacology" xml:lang="en"><term>Amantadine</term><term>Antiviral Agents</term><term>Cyclopentanes</term><term>Enzyme Inhibitors</term><term>Guanidines</term><term>Oseltamivir</term><term>Zanamivir</term></keywords><keywords scheme="MESH" qualifier="analogues et dérivés" xml:lang="fr"><term>Amantadine</term></keywords><keywords scheme="MESH" qualifier="antagonistes et inhibiteurs" xml:lang="fr"><term>Sialidase</term></keywords><keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Influenza A Virus, H5N1 Subtype</term></keywords><keywords scheme="MESH" qualifier="effets des médicaments et des substances chimiques" xml:lang="fr"><term>Sous-type H5N1 du virus de la grippe A</term></keywords><keywords scheme="MESH" qualifier="genetics" xml:lang="en"><term>Influenza A Virus, H5N1 Subtype</term></keywords><keywords scheme="MESH" qualifier="génétique" xml:lang="fr"><term>Sialidase</term><term>Sous-type H5N1 du virus de la grippe A</term></keywords><keywords scheme="MESH" qualifier="isolation & purification" xml:lang="en"><term>Influenza A Virus, H5N1 Subtype</term></keywords><keywords scheme="MESH" qualifier="isolement et purification" xml:lang="fr"><term>Sous-type H5N1 du virus de la grippe A</term></keywords><keywords scheme="MESH" qualifier="pharmacologie" xml:lang="fr"><term>Amantadine</term><term>Antienzymes</term><term>Antiviraux</term><term>Cyclopentanes</term><term>Guanidines</term><term>Oséltamivir</term><term>Zanamivir</term></keywords><keywords scheme="MESH" qualifier="virologie" xml:lang="fr"><term>Grippe chez les oiseaux</term><term>Grippe humaine</term></keywords><keywords scheme="MESH" qualifier="virology" xml:lang="en"><term>Influenza in Birds</term><term>Influenza, Human</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Animals</term><term>Base Sequence</term><term>Birds</term><term>Drug Resistance, Viral</term><term>Humans</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Animaux</term><term>Humains</term><term>Oiseaux</term><term>Résistance virale aux médicaments</term><term>Séquence nucléotidique</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Since 2003, highly pathogenic A(H5N1) influenza viruses have been the cause of large-scale death in poultry and the subsequent infection and death of over 140 humans. A group of 55 influenza A(H5N1) viruses isolated from various regions of South East Asia between 2004 and 2006 were tested for their susceptibility to the anti-influenza drugs the neuraminidase inhibitors and adamantanes. The majority of strains were found to be fully sensitive to the neuraminidase inhibitors oseltamivir carboxylate, zanamivir and peramivir; however two strains demonstrated increased IC50 values. Sequence analysis of these strains revealed mutations in the normally highly conserved residues 116 and 117 of the N1 neuraminidase. Sequence analysis of the M2 gene showed that all of the A(H5N1) viruses from Vietnam, Malaysia and Cambodia contained mutations (L26I and S31N) associated with resistance to the adamantane drugs (rimantadine and amantadine), while strains from Indonesia were found to be a mix of both adamantane resistant (S31N) and sensitive viruses. None of the A(H5N1) viruses from Myanmar contained mutations known to confer adamantane resistance. These results support the use of neuraminidase inhibitors as the most appropriate class of antiviral drug to prevent or treat human A(H5N1) virus infections.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">17112602</PMID><DateCompleted><Year>2007</Year><Month>07</Month><Day>20</Day></DateCompleted><DateRevised><Year>2015</Year><Month>02</Month><Day>19</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Print">0166-3542</ISSN><JournalIssue CitedMedium="Print"><Volume>73</Volume><Issue>3</Issue><PubDate><Year>2007</Year><Month>Mar</Month></PubDate></JournalIssue><Title>Antiviral research</Title><ISOAbbreviation>Antiviral Res</ISOAbbreviation></Journal><ArticleTitle>Susceptibility of highly pathogenic A(H5N1) avian influenza viruses to the neuraminidase inhibitors and adamantanes.</ArticleTitle><Pagination><MedlinePgn>228-31</MedlinePgn></Pagination><Abstract><AbstractText>Since 2003, highly pathogenic A(H5N1) influenza viruses have been the cause of large-scale death in poultry and the subsequent infection and death of over 140 humans. A group of 55 influenza A(H5N1) viruses isolated from various regions of South East Asia between 2004 and 2006 were tested for their susceptibility to the anti-influenza drugs the neuraminidase inhibitors and adamantanes. The majority of strains were found to be fully sensitive to the neuraminidase inhibitors oseltamivir carboxylate, zanamivir and peramivir; however two strains demonstrated increased IC50 values. Sequence analysis of these strains revealed mutations in the normally highly conserved residues 116 and 117 of the N1 neuraminidase. Sequence analysis of the M2 gene showed that all of the A(H5N1) viruses from Vietnam, Malaysia and Cambodia contained mutations (L26I and S31N) associated with resistance to the adamantane drugs (rimantadine and amantadine), while strains from Indonesia were found to be a mix of both adamantane resistant (S31N) and sensitive viruses. None of the A(H5N1) viruses from Myanmar contained mutations known to confer adamantane resistance. These results support the use of neuraminidase inhibitors as the most appropriate class of antiviral drug to prevent or treat human A(H5N1) virus infections.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Hurt</LastName><ForeName>A C</ForeName><Initials>AC</Initials><AffiliationInfo><Affiliation>World Health Organisation Collaborating Centre for Reference and Research on Influenza, 45 Poplar Road, Parkville, Victoria 3052, Australia. Aeron.Hurt@influenzacentre.org</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Selleck</LastName><ForeName>P</ForeName><Initials>P</Initials></Author><Author ValidYN="Y"><LastName>Komadina</LastName><ForeName>N</ForeName><Initials>N</Initials></Author><Author ValidYN="Y"><LastName>Shaw</LastName><ForeName>R</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Brown</LastName><ForeName>L</ForeName><Initials>L</Initials></Author><Author ValidYN="Y"><LastName>Barr</LastName><ForeName>I G</ForeName><Initials>IG</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2006</Year><Month>11</Month><Day>10</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>Antiviral Res</MedlineTA><NlmUniqueID>8109699</NlmUniqueID><ISSNLinking>0166-3542</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000998">Antiviral Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D003517">Cyclopentanes</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D004791">Enzyme Inhibitors</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D006146">Guanidines</NameOfSubstance></Chemical><Chemical><RegistryNumber>20O93L6F9H</RegistryNumber><NameOfSubstance UI="D053139">Oseltamivir</NameOfSubstance></Chemical><Chemical><RegistryNumber>42381-05-5</RegistryNumber><NameOfSubstance UI="C005660">adamantanine</NameOfSubstance></Chemical><Chemical><RegistryNumber>BF4C9Z1J53</RegistryNumber><NameOfSubstance UI="D000547">Amantadine</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.2.1.18</RegistryNumber><NameOfSubstance UI="D009439">Neuraminidase</NameOfSubstance></Chemical><Chemical><RegistryNumber>L6O3XI777I</RegistryNumber><NameOfSubstance UI="D053243">Zanamivir</NameOfSubstance></Chemical><Chemical><RegistryNumber>QW7Y7ZR15U</RegistryNumber><NameOfSubstance UI="C414210">peramivir</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000547" MajorTopicYN="N">Amantadine</DescriptorName><QualifierName UI="Q000031" MajorTopicYN="Y">analogs & derivatives</QualifierName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000998" MajorTopicYN="N">Antiviral Agents</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001483" MajorTopicYN="N">Base Sequence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001717" MajorTopicYN="N">Birds</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003517" MajorTopicYN="N">Cyclopentanes</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D024882" MajorTopicYN="N">Drug Resistance, Viral</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004791" MajorTopicYN="N">Enzyme Inhibitors</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006146" MajorTopicYN="N">Guanidines</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D053124" MajorTopicYN="N">Influenza A Virus, H5N1 Subtype</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000302" MajorTopicYN="N">isolation & purification</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005585" MajorTopicYN="N">Influenza in Birds</DescriptorName><QualifierName UI="Q000821" MajorTopicYN="Y">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007251" MajorTopicYN="N">Influenza, Human</DescriptorName><QualifierName UI="Q000821" MajorTopicYN="Y">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009439" MajorTopicYN="N">Neuraminidase</DescriptorName><QualifierName UI="Q000037" MajorTopicYN="Y">antagonists & inhibitors</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D053139" MajorTopicYN="N">Oseltamivir</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D053243" MajorTopicYN="N">Zanamivir</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2006</Year><Month>08</Month><Day>30</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2006</Year><Month>10</Month><Day>02</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2006</Year><Month>10</Month><Day>05</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2006</Year><Month>11</Month><Day>23</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2007</Year><Month>7</Month><Day>21</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2006</Year><Month>11</Month><Day>23</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">17112602</ArticleId><ArticleId IdType="pii">S0166-3542(06)00312-3</ArticleId><ArticleId IdType="doi">10.1016/j.antiviral.2006.10.004</ArticleId></ArticleIdList></PubmedData></pubmed><affiliations><list><country><li>Australie</li></country></list><tree><noCountry><name sortKey="Barr, I G" sort="Barr, I G" uniqKey="Barr I" first="I G" last="Barr">I G Barr</name><name sortKey="Brown, L" sort="Brown, L" uniqKey="Brown L" first="L" last="Brown">L. Brown</name><name sortKey="Komadina, N" sort="Komadina, N" uniqKey="Komadina N" first="N" last="Komadina">N. Komadina</name><name sortKey="Selleck, P" sort="Selleck, P" uniqKey="Selleck P" first="P" last="Selleck">P. Selleck</name><name sortKey="Shaw, R" sort="Shaw, R" uniqKey="Shaw R" first="R" last="Shaw">R. Shaw</name></noCountry><country name="Australie"><noRegion><name sortKey="Hurt, A C" sort="Hurt, A C" uniqKey="Hurt A" first="A C" last="Hurt">A C Hurt</name></noRegion></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Bois/explor/PoplarV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 003A70 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 003A70 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Bois
|area= PoplarV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= pubmed:17112602
|texte= Susceptibility of highly pathogenic A(H5N1) avian influenza viruses to the neuraminidase inhibitors and adamantanes.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:17112602" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a PoplarV1
| This area was generated with Dilib version V0.6.37. |  |